Zacks Investment Research downgraded VIVUS, Inc. (NASDAQ:VVUS) to Hold in a statement released earlier today.
- Updated: October 6, 2016
Zacks Investment Research has downgraded VIVUS, Inc. (NASDAQ:VVUS) to Hold in a report released on Thursday October 06, 2016.
Only yesterday VIVUS, Inc. (NASDAQ:VVUS) traded -2.65% lower at $1.13. VVUS’s 50-day average is $1.08 and its two hundred day average is $1.23. The last stock price is down -10.77% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Volume of trade was down over the average, with 380,164 shares of VVUS changing hands under the typical 386,534
With a total market value of $0, VIVUS, Inc. has with a one year low of $0.92 and a one year high of $2.25 .
A total of 3 analysts have released a research note on VVUS. zero equity analysts rating the company a strong buy, one brokerage rating the stock a buy, 4 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $7.27.
General Information About VIVUS, Inc. (NASDAQ:VVUS)
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.